Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (16 quarters reported)
$134M in Q4 2017 → $8.26M now. Hover for any quarter.
As reported for the quarter ended September 30, 2021. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Pfizer Inc | 15.6% | New | 30,000 | $1.29M |
| Thermo Fisher Scientific Inc | 13.8% | New | 2,000 | $1.14M |
| Teladoc Health Inc | 10.7% | New | 7,000 | $888K |
| Biomarin Pharmaceutical Inc | 10.3% | New | 11,000 | $850K |
| Johnson & Johnson | 9.8% | New | 5,000 | $808K |
| Fate Therapeutics Inc | 8.6% | Added 20% | 12,000 | $711K |
| HT Horizon Therapeutics Pub L | 8.0% | Added 20% | 6,000 | $657K |
| Arcus Biosciences Inc | 7.2% | Trimmed 15% | 17,000 | $593K |
| Allogene Therapeutics Inc | 4.7% | New | 15,000 | $386K |
| Medtronic PLC | 4.6% | New | 3,000 | $376K |
| PT Proqr Thrapeutics N V | 4.1% | New | 40,000 | $335K |
| Immatics N.v | 1.6% | New | 10,000 | $130K |
| Amicus Therapeutics Inc | 1.2% | New | 10,000 | $96K |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended September 30, 2021 · filed November 15, 2021
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Vertex Pharmaceuticals Inc | Exited | −9,000 | −$1.82M | — |
| Pfizer Inc | New | +30,000 | +$1.29M | 15.6% |
| Thermo Fisher Scientific Inc | New | +2,000 | +$1.14M | 13.8% |
| Teladoc Health Inc | New | +7,000 | +$888K | 10.7% |
| Biomarin Pharmaceutical Inc | New | +11,000 | +$850K | 10.3% |
| Johnson & Johnson | New | +5,000 | +$808K | 9.8% |
| Atara Biotherapeutics Inc | Exited | −50,000 | −$778K | — |
| Zentalis Pharmaceuticals Inc | Exited | −10,000 | −$532K | — |
| TT Tcr2 Therapeutics Inc | Exited | −30,000 | −$492K | — |
| Allogene Therapeutics Inc | New | +15,000 | +$386K | 4.7% |
Showing the 10 largest of 21 changes.
quarter ended June 30, 2021 · filed August 16, 2021
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Vertex Pharmaceuticals Inc | Added | +6,000 | +$1.21M | 28.6% |
| Atara Biotherapeutics Inc | New | +50,000 | +$778K | 12.3% |
| Biomarin Pharmaceutical Inc | Exited | −10,000 | −$755K | — |
| Regeneron Pharmaceuticals | Exited | −1,500 | −$710K | — |
| Abbvie Inc | Exited | −6,000 | −$649K | — |
| Zentalis Pharmaceuticals Inc | New | +10,000 | +$532K | 8.4% |
| TT Tcr2 Therapeutics Inc | New | +30,000 | +$492K | 7.8% |
| HT Horizon Therapeutics Pub L | New | +5,000 | +$468K | 7.4% |
| Revolution Medicines Inc | Exited | −10,000 | −$459K | — |
| Accolade Inc | New | +7,000 | +$380K | 6.0% |
Showing the 10 largest of 21 changes.
quarter ended March 31, 2021 · filed May 17, 2021
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Regeneron Pharmaceuticals | New | +1,500 | +$710K | 11.5% |
| Bristol-myers Squibb Co | Exited | −11,327 | −$703K | — |
| Revolution Medicines Inc | New | +10,000 | +$459K | 7.4% |
| Fate Therapeutics Inc | Added | +4,760 | +$393K | 10.7% |
| IH Iqvia Hldgs Inc | Exited | −2,094 | −$375K | — |
| Igm Biosciences Inc | Exited | −4,000 | −$353K | — |
| GO Gritstone Oncology Inc | New | +37,000 | +$349K | 5.6% |
| Ardelyx Inc | New | +50,000 | +$331K | 5.3% |
| GP Gw Pharmaceuticals PLC | Exited | −2,788 | −$322K | — |
| Neurocrine Biosciences Inc | Exited | −3,089 | −$296K | — |
Showing the 10 largest of 21 changes.
quarter ended December 31, 2020 · filed February 16, 2021
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Abbvie Inc | Trimmed | −143,763 | −$15.4M | 7.8% |
| Fate Therapeutics Inc | Trimmed | −150,057 | −$13.7M | 4.6% |
| Biomarin Pharmaceutical Inc | Trimmed | −154,462 | −$13.5M | 14.7% |
| Bristol-myers Squibb Co | Trimmed | −201,987 | −$12.5M | 11.0% |
| Vertex Pharmaceuticals Inc | Trimmed | −41,904 | −$9.9M | 11.4% |
| IH Iqvia Hldgs Inc | Trimmed | −37,338 | −$6.69M | 5.8% |
| AP Arena Pharmaceuticals Inc | Trimmed | −81,797 | −$6.28M | 4.5% |
| M Myokardia Inc | Exited | −42,186 | −$5.75M | — |
| GP Gw Pharmaceuticals PLC | Trimmed | −49,700 | −$5.74M | 5.0% |
| Tg Therapeutics Inc | Trimmed | −89,153 | −$4.64M | 4.7% |
Showing the 10 largest of 21 changes.
quarter ended September 30, 2020 · filed November 16, 2020
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| AP Alexion Pharmaceuticals Inc | Exited | −85,000 | −$9.54M | — |
| Biomarin Pharmaceutical Inc | Added | +115,292 | +$8.77M | 12.0% |
| Amgen Inc | Exited | −33,000 | −$7.78M | — |
| Vertex Pharmaceuticals Inc | Added | +22,684 | +$6.17M | 11.7% |
| Teladoc Health Inc | New | +21,500 | +$4.71M | 4.5% |
| HT Horizon Therapeutics Pub Ltd | Exited | −84,626 | −$4.7M | — |
| Abbvie Inc | Added | +38,439 | +$3.37M | 12.4% |
| GP Gw Pharmaceuticals PLC | Added | +30,488 | +$2.97M | 4.9% |
| MP Momenta Pharmaceuticals Inc | Exited | −88,000 | −$2.93M | — |
| Revolution Medicines Inc | New | +81,000 | +$2.82M | 2.7% |
Showing the 10 largest of 23 changes.
quarter ended June 30, 2020 · filed August 14, 2020
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Abbvie Inc | New | +110,000 | +$10.8M | 11.8% |
| CN Cigna Corp New | Exited | −54,748 | −$9.7M | — |
| AP Alexion Pharmaceuticals Inc | New | +85,000 | +$9.54M | 10.5% |
| Vertex Pharmaceuticals Inc | Trimmed | −30,148 | −$8.75M | 7.1% |
| Amgen Inc | New | +33,000 | +$7.78M | 8.5% |
| Cvs Health Corp | Exited | −130,000 | −$7.71M | — |
| Mckesson Corp | Exited | −51,000 | −$6.9M | — |
| Biomarin Pharmaceutical Inc | Trimmed | −53,290 | −$6.57M | 6.7% |
| Biogen Inc | Exited | −18,000 | −$5.7M | — |
| IH Iqvia Hldgs Inc | New | +40,000 | +$5.68M | 6.2% |
Showing the 10 largest of 27 changes.
quarter ended March 31, 2020 · filed May 14, 2020
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Cvs Health Corp | New | +130,000 | +$7.71M | 9.3% |
| Mckesson Corp | New | +51,000 | +$6.9M | 8.3% |
| Abbvie Inc | Exited | −76,957 | −$6.81M | — |
| IH Iqvia Hldgs Inc | Exited | −40,585 | −$6.27M | — |
| Biogen Inc | New | +18,000 | +$5.7M | 6.9% |
| S Sientra Inc | Exited | −384,809 | −$3.44M | — |
| CD Centene Corp Del | New | +47,000 | +$2.79M | 3.4% |
| CN Cigna Corp New | Added | +14,748 | +$2.61M | 11.7% |
| Thermo Fisher Scientific Inc | Added | +8,937 | +$2.53M | 6.5% |
| Bristol-myers Squibb Co | Added | +44,165 | +$2.46M | 11.9% |
Showing the 10 largest of 21 changes.
quarter ended December 31, 2019 · filed February 14, 2020
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Gilead Sciences Inc | Exited | −197,916 | −$12.5M | — |
| Humana Inc | Trimmed | −27,058 | −$9.92M | 1.9% |
| CN Cigna Corp New | New | +40,000 | +$8.18M | 10.7% |
| CD Centene Corp Del | Exited | −147,000 | −$6.36M | — |
| Merck & Co Inc | Exited | −74,000 | −$6.23M | — |
| Thermo Fisher Scientific Inc | Trimmed | −19,017 | −$6.18M | 4.2% |
| Abbvie Inc | Trimmed | −55,043 | −$4.87M | 8.9% |
| Caredx Inc | Exited | −184,855 | −$4.18M | — |
| Bristol Myers Squibb Co | Trimmed | −65,105 | −$4.18M | 11.2% |
| Tandem Diabetes Care Inc | New | +50,000 | +$2.98M | 3.9% |
Showing the 10 largest of 20 changes.
Loading...
